Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma

C. Danial, B. Lingala, Raymond Balise, A. E. Oro, S. Reddy, A. Colevas, A. L S Chang

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8-14 months. However, these estimates are based on analyses of case reports published prior to 1984. Objectives To assess an updated OS in patients with metastatic BCC at a single academic institution. Methods Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy-confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan-Meier analysis was used to determine OS and progression-free survival (PFS). Results Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7·3 years [95% confidence interval (CI) 1·6-∞]; median PFS was 3·4 years (95% CI 1·1-5·2). Conclusions Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported. What's already known about this topic? The estimate of overall survival (OS) from date of diagnosis of distant metastatic basal cell carcinoma (BCC) to death is 8-14 months. This estimate was published in 1984 and needs to be updated. What does this study add? We explored OS in a series of patients from 1997 to 2011 at Stanford Hospital and Clinics. Our findings suggest that OS in patients with metastatic BCC may be more favourable than previously reported.

Original languageEnglish (US)
Pages (from-to)673-676
Number of pages4
JournalBritish Journal of Dermatology
Volume169
Issue number3
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Basal Cell Carcinoma
Survival
Disease-Free Survival
Confidence Intervals
Kaplan-Meier Estimate
Medicine
Neoplasm Metastasis
Biopsy

ASJC Scopus subject areas

  • Dermatology

Cite this

Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. / Danial, C.; Lingala, B.; Balise, Raymond; Oro, A. E.; Reddy, S.; Colevas, A.; Chang, A. L S.

In: British Journal of Dermatology, Vol. 169, No. 3, 09.2013, p. 673-676.

Research output: Contribution to journalArticle

Danial, C. ; Lingala, B. ; Balise, Raymond ; Oro, A. E. ; Reddy, S. ; Colevas, A. ; Chang, A. L S. / Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. In: British Journal of Dermatology. 2013 ; Vol. 169, No. 3. pp. 673-676.
@article{8f0de2d8a1f14aaf979af546336435d3,
title = "Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma",
abstract = "Background Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8-14 months. However, these estimates are based on analyses of case reports published prior to 1984. Objectives To assess an updated OS in patients with metastatic BCC at a single academic institution. Methods Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy-confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan-Meier analysis was used to determine OS and progression-free survival (PFS). Results Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7·3 years [95{\%} confidence interval (CI) 1·6-∞]; median PFS was 3·4 years (95{\%} CI 1·1-5·2). Conclusions Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported. What's already known about this topic? The estimate of overall survival (OS) from date of diagnosis of distant metastatic basal cell carcinoma (BCC) to death is 8-14 months. This estimate was published in 1984 and needs to be updated. What does this study add? We explored OS in a series of patients from 1997 to 2011 at Stanford Hospital and Clinics. Our findings suggest that OS in patients with metastatic BCC may be more favourable than previously reported.",
author = "C. Danial and B. Lingala and Raymond Balise and Oro, {A. E.} and S. Reddy and A. Colevas and Chang, {A. L S}",
year = "2013",
month = "9",
doi = "10.1111/bjd.12333",
language = "English (US)",
volume = "169",
pages = "673--676",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma

AU - Danial, C.

AU - Lingala, B.

AU - Balise, Raymond

AU - Oro, A. E.

AU - Reddy, S.

AU - Colevas, A.

AU - Chang, A. L S

PY - 2013/9

Y1 - 2013/9

N2 - Background Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8-14 months. However, these estimates are based on analyses of case reports published prior to 1984. Objectives To assess an updated OS in patients with metastatic BCC at a single academic institution. Methods Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy-confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan-Meier analysis was used to determine OS and progression-free survival (PFS). Results Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7·3 years [95% confidence interval (CI) 1·6-∞]; median PFS was 3·4 years (95% CI 1·1-5·2). Conclusions Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported. What's already known about this topic? The estimate of overall survival (OS) from date of diagnosis of distant metastatic basal cell carcinoma (BCC) to death is 8-14 months. This estimate was published in 1984 and needs to be updated. What does this study add? We explored OS in a series of patients from 1997 to 2011 at Stanford Hospital and Clinics. Our findings suggest that OS in patients with metastatic BCC may be more favourable than previously reported.

AB - Background Metastatic basal cell carcinoma (BCC) is a rare but life-threatening condition. Prior estimates of overall survival (OS) from time of diagnosis of distant metastasis to death are approximately 8-14 months. However, these estimates are based on analyses of case reports published prior to 1984. Objectives To assess an updated OS in patients with metastatic BCC at a single academic institution. Methods Using patients seen from 1997 to 2011, a retrospective chart review was performed on biopsy-confirmed cases of distant metastatic BCC at Stanford University School of Medicine. Kaplan-Meier analysis was used to determine OS and progression-free survival (PFS). Results Ten consecutive cases of distant metastatic BCC were identified. Median OS was 7·3 years [95% confidence interval (CI) 1·6-∞]; median PFS was 3·4 years (95% CI 1·1-5·2). Conclusions Our findings suggest that OS in patients with distant metastatic BCC may be more favourable than previously reported. What's already known about this topic? The estimate of overall survival (OS) from date of diagnosis of distant metastatic basal cell carcinoma (BCC) to death is 8-14 months. This estimate was published in 1984 and needs to be updated. What does this study add? We explored OS in a series of patients from 1997 to 2011 at Stanford Hospital and Clinics. Our findings suggest that OS in patients with metastatic BCC may be more favourable than previously reported.

UR - http://www.scopus.com/inward/record.url?scp=84883339094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883339094&partnerID=8YFLogxK

U2 - 10.1111/bjd.12333

DO - 10.1111/bjd.12333

M3 - Article

C2 - 23521172

AN - SCOPUS:84883339094

VL - 169

SP - 673

EP - 676

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 3

ER -